Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709585 | 0.88 | GAA (0.48) | GAANPC1MAPTNPSR1ERN1 | |
| SCHEMBL11527141 | 0.82 | GAA (0.48) | GAANPC1MAPTNPSR1ACLY | |
| SCHEMBL11519952 | 0.82 | CYP3A4 (0.56) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL16198301 | 0.82 | GAA (0.48) | GAANPC1MAPTNPSR1ERN1 | |
| SCHEMBL1426410 | 0.80 | TUBB4A (0.47) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL2084949 | 0.80 | MAP3K14 (0.44) | GAANPC1MAPTNPSR1ERN1 | |
| SCHEMBL16047636 | 0.78 | MAPT (0.53) | GAANPC1MAPTNPSR1ERN1 | |
| SCHEMBL31506852 | 0.78 | MAPT (0.48) | GAANPC1MAPTNPSR1ERN1 | |
| SCHEMBL1854071 | 0.78 | GAA (0.41) | GAANPC1MAPTNPSR1ERN1 | |
| SCHEMBL30254383 | 0.78 | MAPT (0.53) | GAANPC1MAPTNPSR1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300401-B1 | THIAZOLE DERIVATIVES FOR USE AS ANTIINFLAMMATORIES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1669070-A2 | 2-imino-thiazolidine and -oxazolidine derivatives for use as antiinflammatory agents | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050222226-A1 | Five-membered cyclic compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2005-10-06 | — | — | US | disclosed |
| US-6919361-B2 | Five-membered-ring compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040072827-A1 | Five-membered-ring compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1300401-A1 | FIVE-MEMBERED-RING COMPOUND | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
| EP-0477819-B1 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-03-15 | — | — | EP | disclosed |
| US-5200422-A | Benzimidazole derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-04-06 | — | — | US | disclosed |
| EP-0477819-A2 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1992-04-01 | — | — | EP | disclosed |
| US-3939176-A | 1-PHENYL-3-PHENYLUREIDO-PYRAZOLONES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072827-A1 | Five-membered-ring compound | EPX, IL5, CCR9 | GAA 4650/4885NPC1 4342/4885MAPT 4768/4885 |
| US-20050222226-A1 | Five-membered cyclic compounds | EPX, CCL11, CCR9 | GAA 4668/4885NPC1 4372/4885MAPT 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.